Clinical study on sitagliptin combined with candesartan in treatment of diabetic nephropathy

Hua YANG,Shu-jin WANG,Hong ZUO,Guo-hong LI,Lei MA,Yu NIU,Jia FENG,Xu-feng LIU,Song-fang LIU,Ting QI
DOI: https://doi.org/10.7501/j.issn.1674-5515.2017.11.030
2017-01-01
Abstract:Objective To investigate the clinical efficacy of sitagliptin combined with candesartan in treatment of diabetic nephropathy. Methods Patients (130 cases) with diabetic nephropathy in Ninth Hospital of Xi'an from March 2016 to March 2017 were randomly divided into control (65 cases) and treatment (65 cases) groups. Patients in the control group were po administered with Candesartan Cilexetil Tablets, 8 mg/time, once daily. Patients in the treatment group were po administered with Sitagliptin Phosphate Tablets on the basis of the control group, 100 mg/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the blood glucose and renal function indexes, cystatin C and homocysteine levels, serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.54% and 93.85%, respectively, and there were differences between two groups (P < 0.05). After treatment, the FPG, 2 h PG, HbAlc, Scr, BUN, and ACR in two groups were significantly decreased (P < 0.05). And blood glucose and renal function indexes in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the cystatin C and homocysteine levels in two groups were significantly decreased (P < 0.05). And these indexes in the treatment group decreased more significantly than those in the control group (P < 0.05). After treatment, the β2-MG and γ-GT levels in two groups were significantly decreased (P < 0.05). And these indexes in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion Sitagliptin combined with candesartan can effectively control blood glucose in treatment of diabetic nephropathy, and can significantly improve renal function and oxidative stress state.
What problem does this paper attempt to address?